Ignitis Renewables completes Silesia wind farm II with 137 MW capacity in Poland

Darius Maikštėnas CEO
Darius Maikštėnas CEO
0Comments

Ignitis Renewables has announced that the Silesia wind farm II, located in the Opole Voivodeship in southern Poland, has reached its commercial operation date. The facility consists of 38 Nordex N117/3600 wind turbines and has a total installed capacity of 137 megawatts.

According to Darius Maikštėnas, CEO of Ignitis Group, “Silesia wind farm is an important part of our green generation portfolio. Every project of this scale enables us to move towards our strategic priority to deliver 4–5 GW of installed green capacities by 2030. We welcome the consolidation of our operations in Poland, which contributes to the green transformation of the entire region.”

The company states that Silesia wind farm II is among the largest wind farms currently operating in Poland and can supply enough electricity for about 177,000 households each year.

Ignitis Renewables says that completing this project strengthens its presence in Poland and supports its aim to develop a fully green and secure energy system in the region. The total investment for the wind farm—including both acquisition and construction—could reach up to EUR 240 million.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.